MigraineMind research summary
Magnitude and Determinants of Placebo Response in Acute Migraine Trials: A Systematic Review and Meta-Analysis.
Neurology | 2026
Systematic review / meta-analysisSummary
Migraine is a common and debilitating neurological disorder affecting many people. This study examined the placebo response in acute migraine clinical trials. Researchers analyzed 126 randomized controlled trials with 24,614 participants. The mean age of participants ranged from 34.8 to 45.2 years, with 65% to 97% being female. The pooled 2-hour pain freedom rate after placebo was 11%. Intranasal and subcutaneous methods had higher rates at 14% and 13%, respectively, while oral methods showed 10%. Factors such as severe baseline headache and less active treatment increased placebo responsiveness. Notably, placebo response rates grew significantly over time. The study also found that 34% achieved 2-hour pain relief, 9% sustained pain freedom, and 52% needed rescue medication. Placebo responses varied among non-Caucasian individuals and in Asian countries. The findings highlight the importance of placebo effects in migraine treatments and suggest improvements for future trial designs. Clinical relevance: This research emphasizes the growing importance of placebo responses in migraine trials, potentially guiding better treatment strategies and trial designs.
Key Learning Points
- Migraine affects many individuals and can significantly impact their quality of life.
- The placebo response in migraine trials is notable, with a pooled pain freedom rate of 11% after placebo treatment.
- Different administration methods show varying placebo response rates, with intranasal and subcutaneous methods performing better than oral methods.
- Certain factors, like the severity of the initial headache, can increase the likelihood of a positive placebo response.
- Understanding placebo effects can help improve migraine treatment strategies and the design of future clinical trials.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.